

## DAFTAR PUSTAKA

- Arita H , Kinoshita M, Kawaguchi A, et al. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. *Sci Rep.*2018;8(1):11773.
- Bou Zerdan, M. and Assi, H.I. (2021) “Oligodendroglioma: A Review of Management and Pathways,” *Frontiers in Molecular Neuroscience*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fnmol.2021.722396>.
- Bou Zerdan, M. *et al.* (2022) “Latest updates on cellular and molecular biomarkers of gliomas,” *Frontiers in Oncology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fonc.2022.1030366>.
- Chien, L.-N. *et al.* (2015) “International Differences in Treatment and Clinical Outcomes for High Grade Glioma,” *PLOS ONE*, 10(6), pp. e0129602-. Available at: <https://doi.org/10.1371/journal.pone.0129602>.
- Choi, J., Lee, E.Y., Shin, K.J., Minn, Y.K., Kim, J. & Kim, S.H., 2013. IDH1 mutation analysis in low cellularity specimen: A limitation of diagnostic accuracy and a proposal for the diagnostic procedure. *Pathology – Research and Practice*, 209(5), pp.284–290. <https://doi.org/10.1016/j.prp.2013.02.010>.
- Cohen, A.L., Holmen, S.L. & Colman, H., 2013. IDH1 and IDH2 mutations in gliomas. *Current Neurology and Neuroscience Reports*, 13(5), p.345. [doi:10.1007/s11910-013-0345-4](https://doi.org/10.1007/s11910-013-0345-4).



Fellah, S. *et al.* (2013) “Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?,” *American Journal of Neuroradiology*, 34(7), p. 1326. Available at: <https://doi.org/10.3174/ajnr.A3352>.

Gerritsen, J.K.W. *et al.* (2022) “Safe surgery for glioblastoma: Recent advances and modern challenges,” *Neuro-Oncology Practice*, 9(5), pp. 364–379. Available at: <https://doi.org/10.1093/nop/npac019>.

Girardi, F. *et al.* (2023) “Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3),” *Neuro-Oncology*, 25(3), pp. 580–592. Available at: <https://doi.org/10.1093/neuonc/noac217>.

Guo, X., Gu, L., Li, Y., Zheng, Z., Chen, W., Wang, Y., Wang, Y., Xing, H., Shi, Y., Liu, D., Yang, T., Xia, Y., Li, J., Wu, J., Zhang, K., Liang, T., Wang, H., Liu, Q., Jin, S., ... Ma, W. (2023) 'Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors', *Frontiers in Oncology*, 13, p. 1200815. [doi:10.3389/fonc.2023.1200815](https://doi.org/10.3389/fonc.2023.1200815).

Gusyatiner, O. and Hegi, M.E. (2018) “Glioma epigenetics: From subclassification to novel treatment options,” *Seminars in Cancer Biology*, 51, pp. 50–58. Available at: <https://doi.org/https://doi.org/10.1016/j.semcancer.2017.11.010>.



- Hambardzumyan, D., Gutmann, D.H. and Kettenmann, H. (2015) “The role of microglia and macrophages in glioma maintenance and progression,” *Nature Neuroscience*. Nature Publishing Group, pp. 20–27. Available at: <https://doi.org/10.1038/nn.4185>.
- Ilic, I. and Ilic, M. (2023) “International patterns and trends in the brain cancer incidence and mortality: An observational study based on the global burden of disease,” *Heliyon*, 9(7). Available at: <https://doi.org/10.1016/j.heliyon.2023.e18222>.
- Kinslow, C.J. et al. (2024) 'Association of Age with IDH-Status and Progression in Diffuse Gliomas', *International Journal of Radiation OncologyBiologyPhysics*. doi:10.1016/j.ijrobp.2024.06.016.
- Larjavaara, S. *et al.* (2007) “Incidence of gliomas by anatomic location,” *Neuro-Oncology*, 9(3), pp. 319–325. Available at: <https://doi.org/10.1215/15228517-2007-016>.
- Lee, K. *et al.* (2023) “Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis,” *Scientific Reports*, 13(1), p. 6761. Available at: <https://doi.org/10.1038/s41598-023-32153-y>.
- Lin Z, Yang R, Li K, Yi G, Li Z, Guo J, Zhang Z, Junxiang P, Liu Y, Qi S, Huang G. Establishment of age group classification for risk stratification in glioma patients. *BMC Neurol*. 2020 Aug 20;20(1):310. doi: [10.1186/s12883-020-01888-w](https://doi.org/10.1186/s12883-020-01888-w). PMID: 32819307; PMCID: PMC7439690.

- de Leeuw, B.I. *et al.* (2019) “Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: A systematic review and meta-analysis,” *Neuro-Oncology Advances*. Oxford University Press. Available at: <https://doi.org/10.1093/noajnl/vdz032>.
- Louis, D.N. *et al.* (2021) “The 2021 WHO classification of tumors of the central nervous system: A summary,” *Neuro-Oncology*, 23(8), pp. 1231–1251. Available at: <https://doi.org/10.1093/neuonc/noab106>.
- MacKintosh, C. *et al.* (2020) “Does location matter? Characterisation of the anatomic locations, molecular profiles, and clinical features of gliomas,” *Neurologia i Neurochirurgia Polska*, 54(5), pp. 456–465. Available at: <https://doi.org/10.5603/PJNNS.a2020.0067>.
- Malueka, R.G. *et al.* (2020) “Clinicopathological features and prognosis of Indonesian patients with gliomas with IDH mutation: Insights into its significance in a Southeast Asian population,” *Asian Pacific Journal of Cancer Prevention*, 21(8), pp. 2287–2295. Available at: <https://doi.org/10.31557/APJCP.2020.21.8.2287>.
- Mishra, S. and Iyengar, S. (2023) 'Prevalence of High Grade Glioma Grade III and IV in tertiary care hospital', *IOSR Journal of Dental and Medical Sciences*, 22(3 Ser.16), pp. 57–60. [doi:10.9790/0853-2203165760](https://doi.org/10.9790/0853-2203165760).
- Moffet, J.J.D., Fatunla, O.E., Freytag, L., Kriel, J., Jones, J.J., Roberts-Thomson, S.J., Pavenko, A., Scoville, D.K., Zhang, L., Liang, Y., Morokoff, A.P., Whittle, J.R., Freytag, S. & Best, S.A., 2023. Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains.



Neuro-Oncology Advances, 5(1), vdad142.

<https://doi.org/10.1093/noajnl/vdad142>.

Noiphithak R, Veerasarn K. Clinical predictors for survival and treatment outcome of high-grade glioma in Prasat Neurological Institute. *Asian J Neurosurg.* 2017 Jan-Mar;12(1):28-33. doi: [10.4103/1793-5482.148791](https://doi.org/10.4103/1793-5482.148791). PMID: 28413528; PMCID: PMC5379799.

Ostrom, Q.T., Kinnersley, B., Wrensch, M.R. et al. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. *Sci Rep* 8, 7352 (2018). <https://doi.org/10.1038/s41598-018-24580-z>

Park, Y.W. *et al.* (2023) “The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1—Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas,” *Journal of Magnetic Resonance Imaging*, 58(3), pp. 677–689. Available at: <https://doi.org/10.1002/jmri.28743>.

Park *et al.* (2024). IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation. *bioRxiv* 2024.10.17.618976; doi: <https://doi.org/10.1101/2024.10.17.618976>

Quan, L., Uyeda, A. and Muramatsu, R. (2022) “Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination,” *Inflammation and Regeneration*. BioMed Central Ltd. Available at: <https://doi.org/10.1186/s41232-022-00193-y>.



Sahm, F. *et al.* (2023) “Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; An EANO guideline,” *Neuro-Oncology*. Oxford University Press, pp. 1731–1749. Available at: <https://doi.org/10.1093/neuonc/noad100>.

Salari, N. *et al.* (2023) “The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis,” *European Journal of Medical Research*, 28(1), p. 39. Available at: <https://doi.org/10.1186/s40001-023-01011-y>.

Sharma, N. *et al.* (2023) “Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials,” *Neuro-Oncology Advances*. Oxford University Press. Available at: <https://doi.org/10.1093/noajnl/vdad053>.

Simpson, J.R. *et al.* (1993) “Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive radiation therapy oncology group (RTOG) clinical trials,” *International Journal of Radiation Oncology, Biology, Physics*, 26(2), pp. 239–244. Available at: [https://doi.org/10.1016/0360-3016\(93\)90203-8](https://doi.org/10.1016/0360-3016(93)90203-8).

Sizoo, E.M. *et al.* (2010) “Symptoms and problems in the end-of-life phase of high-grade glioma patients,” *Neuro-Oncology*, 12(11), pp. 1162–1166. Available at: <https://doi.org/10.1093/neuonc/nop045>.



- Sterckx, W. *et al.* (2013) “The impact of a high-grade glioma on everyday life: A systematic review from the patient’s and caregiver’s perspective,” *European Journal of Oncology Nursing*, 17(1), pp. 107–117. Available at: <https://doi.org/https://doi.org/10.1016/j.ejon.2012.04.006>.
- Tira A, Buckingham L. Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis. *Int J Exp Pathol*. 2021 Dec;102(6):232-241. doi: 10.1111/iep.12402. Epub 2021 Oct 30. PMID: 34716726; PMCID: PMC8626623.
- Valvi, S., Fouladi, M., Fisher, M.J. and Gottardo, N.G. (2025) 'IDH mutant high-grade gliomas', *Frontiers in Molecular Neuroscience*, 18, p. 1662414. doi:10.3389/fnmol.2025.1662414.
- Wang, Y., Liu, S., Fan, X. et al. (2015). Age-associated brain regions in gliomas: a volumetric analysis. *J Neurooncol* 123, 299–306. <https://doi.org/10.1007/s11060-015-1798-x>
- Wang et al. 2022, Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas, *Neuro-Oncology*, Volume 24, Issue 2, February 2022, Pages 302–310, <https://doi.org/10.1093/neuonc/noab199>
- Wang G, Zhou H, Tian L, Yan T, Han X, Chen P, Li H, Wang W, Xiao Z, Hou L, Xue X. A Prognostic DNA Damage Repair Genes Signature and Its Impact on Immune Cell Infiltration in Glioma. *Front Oncol*. 2021 May 28;11:682932. doi: 10.3389/fonc.2021.682932. PMID: 34123852; PMCID: PMC8193723.



Wang, J., Xia, J., Wu, P. et al., 2025. An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma. *Scientific Reports*, 15, p.33194. <https://doi.org/10.1038/s41598-025-17539-4>.

Yang, Z. *et al.* (2023) “A review on surgical treatment options in gliomas,” *Frontiers in Oncology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fonc.2023.1088484>.